Broadening of the T-Cell Repertoire to HIV-1 Gag p24 by Vaccination of HLA-A2/DR Transgenic Mice with Overlapping Peptides in the CAF05 Adjuvant

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Korsholm, Karen S ^a   Karlsson, Ingrid ^a   Tang, Sheila T ^a,b   Brandt, Lea ^a   Agger, Else Marie ^a   Aagaard, Claus ^a   Andersen, Peter ^a   Fomsgaard, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Reagent Partnership Division   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LIPOSOME; SYNTHETIC PEPTIDE; HLA A2 ANTIGEN; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SPLEEN CELL; TRANSGENIC MOUSE; AMINO ACID SEQUENCE; ANALYSIS OF VARIANCE; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOLECULAR GENETICS;

AIDS VACCINES; AMINO ACID SEQUENCE; ANALYSIS OF VARIANCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES, T-LYMPHOCYTE; HIV CORE PROTEIN P24; HIV-1; HLA-A2 ANTIGEN; IMMUNITY, CELLULAR; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA;

EID: 84877852140     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063575     Document Type: Article

References (57)

1. Rugg D, Marais H, Carael M, De Lay P, Warner-Smith M, (2009) Are we on course for reporting on the Millennium Development Goals in 2015? J Acquir Immune Defic Syndr 52Suppl 2: S69-76.
2. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
3. Barouch DH, Craiu A, Santra S, Egan MA, Schmitz JE, et al. (2001) Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol 75: 2462-2467.
4. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. (2006) Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7: 173-178.
5. Walker BD, Burton DR, (2008) Toward an AIDS vaccine. Science 320: 760-764.
6. Karlsson I, Kloverpris H, Jensen KJ, Stryhn A, Buus S, et al. (2012) Identification of Conserved Subdominant HIV Type 1 CD8(+) T Cell Epitopes Restricted Within Common HLA Supertypes for Therapeutic HIV Type 1 Vaccines. AIDS Res Hum Retroviruses 28: 1434-1443.
7. Vanham G, Van Gulck E, (2012) Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology 9: 72.
8. Stratov I, Dale CJ, Chea S, McCluskey J, Kent SJ, (2005) Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 79: 7728-7737.
9. Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, et al. (2002) Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 76: 6138-6146.
10. De Rose R, Fernandez CS, Smith MZ, Batten CJ, Alcantara S, et al. (2008) Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog 4: e1000055.
11. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53.
12. Pettersen FO, Tasken K, Kvale D, (2010) Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection. Clin Exp Immunol 161: 315-323.
13. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, et al. (2007) Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 178: 2746-2754.
14. Chea S, Dale CJ, De Rose R, Ramshaw IA, Kent SJ, (2005) Enhanced cellular immunity in macaques following a novel peptide immunotherapy. J Virol 79: 3748-3757.
15. Mason RD, Alcantara S, Peut V, Loh L, Lifson JD, et al. (2009) Inactivated simian immunodeficiency virus-pulsed autologous fresh blood cells as an immunotherapy strategy. J Virol 83: 1501-1510.
16. Garcia F, Routy JP, (2011) Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 29: 6454-6463.
17. Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, et al. (2009) Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 23: 1329-1340.
18. Karlsson I, Brandt L, Vinner L, Kromann I, Andreasen LV, et al. (2013) Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clinical Immunology 146: 120-130.
19. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, et al. (2010) Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol 84: 10543-10557.
20. Fomsgaard A, Karlsson I, Gram G, Schou C, Tang S, et al. (2011) Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine 29: 7067-7074.
21. Hansen J, Lindenstrom T, Lindberg-Levin J, Aagaard C, Andersen P, et al. (2012) CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice. Cancer Immunol Immunother 61: 893-903.
22. Nordly P, Rose F, Christensen D, Nielsen HM, Andersen P, et al. (2011) Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J Control Release 150: 307-317.
23. Pajot A, Michel ML, Fazilleau N, Pancre V, Auriault C, et al. (2004) A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 34: 3060-3069.
24. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, et al. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718: 22-31.
25. Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, et al. (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 59: 1489-1501.
26. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S, (2010) NetMHCIIpan-2.0- Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 6: 9.
27. Erup Larsen M, Kloverpris H, Stryhn A, Koofhethile CK, Sims S, et al. (2011) HLArestrictor-a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 63: 43-55.
28. (2012) Los Alamos HIV Molecular Immunology database.
29. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P, (2004) Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72: 1608-1617.
30. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, et al. (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176: 7335-7345.
31. Fujimoto C, Nakagawa Y, Ohara K, Takahashi H, (2004) Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol 16: 55-63.
32. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
33. Liu Y, Li F, Liu Y, Hong K, Meng X, et al. (2011) HIV fragment gag vaccine induces broader T cell response in mice. Vaccine 29: 2582-2589.
34. Benlahrech A, Meiser A, Herath S, Papagatsias T, Athanasopoulos T, et al. (2012) Fragmentation of SIV-gag Vaccine Induces Broader T Cell Responses. PLoS One 7: e48038.
35. Aagaard CS, Hoang TTKT, Vingsbo-Lundberg C, Dietrich J, Andersen P, (2009) Quality and Vaccine Efficacy of CD4+ T Cell Responses Directed to Dominant and Subdominant Epitopes in ESAT-6 from Mycobacterium tuberculosis. The Journal of Immunology 183: 2659-2668.
36. Powell MF, Grey H, Gaeta F, Sette A, Colón S, (1992) Peptide stability in drug development: A comparison of peptide reactivity in different biological media. Journal of Pharmaceutical Sciences 81: 731-735.
37. Watts C, (2001) Antigen processing in the endocytic compartment. Current Opinion in Immunology 13: 26-31.
38. Craiu A, Akopian T, Goldberg A, Rock KL, (1997) Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proceedings of the National Academy of Sciences 94: 10850-10855.
39. Kohler H, Goudsmit J, Nara P, (1992) Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination. J Acquir Immune Defic Syndr 5: 1158-1168.
40. Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, et al. (1999) Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 179: 637-645.
41. Brandt L, Oettinger T, Holm A, Andersen AB, Andersen P, (1996) Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 157: 3527-3533.
42. Hudson CP (2009) HIV-1 step study. Lancet 373: 805-806; author reply 806.
43. Pion S, Christianson GJ, Fontaine P, Roopenian DC, Perreault C, (1999) Shaping the repertoire of cytotoxic T-lymphocyte responses: explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens. Blood 93: 952-962.
44. Yewdell JW, Bennink JR, (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17: 51-88.
45. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, et al. (2002) Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168: 4391-4398.
46. Roy-Proulx G, Meunier MC, Lanteigne AM, Brochu S, Perreault C, (2001) Immunodomination results from functional differences between competing CTL. Eur J Immunol 31: 2284-2292.
47. Kloverpris HN, Karlsson I, Thorn M, Buus S, Fomsgaard A, (2009) Immune hierarchy among HIV-1 CD8+ T cell epitopes delivered by dendritic cells depends on MHC-I binding irrespective of mode of loading and immunization in HLA-A*0201 mice. APMIS 117: 849-855.
48. Harcourt GC, Garrard S, Davenport MP, Edwards A, Phillips RE, (1998) HIV-1 variation diminishes CD4 T lymphocyte recognition. J Exp Med 188: 1785-1793.
49. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447-1450.
50. Daucher M, Price DA, Brenchley JM, Lamoreaux L, Metcalf JA, et al. (2008) Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J Virol 82: 4102-4114.
51. Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, et al. (2001) Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol 75: 4195-4207.
52. Richmond M, McKinnon LR, Kiazyk SA, Wachihi C, Kimani M, et al. (2011) Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function. J Virol 85: 1275-1286.
53. Brander C, Yang OO, Jones NG, Lee Y, Goulder P, et al. (1999) Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences. J Virol 73: 10191-10198.
54. Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, et al. (2004) Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 78: 4463-4477.
55. Lazaro E, Theodorou I, Legrand E, Recordon-Pinson P, Boucher S, et al. (2005) Sequences of clustered epitopes in Gag and Nef potentially presented by predominant class I human leukocyte antigen (HLA) alleles A and B expressed by human immunodeficiency virus type 1 (HIV-1)-infected patients in Vietnam. AIDS Res Hum Retroviruses 21: 586-591.
56. Malhotra U, Holte S, Dutta S, Berrey MM, Delpit E, et al. (2001) Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 107: 505-517.
57. Koeppe JR, Campbell TB, Rapaport EL, Wilson CC, (2006) HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J Acquir Immune Defic Syndr 41: 140-148.